Rare Daily Staff
PerkinElmer said it will acquire Sirion Biotech, a global provider of viral vector-based technologies to improve the delivery of cell and gene therapies, complementing its growing offerings in cell and gene therapy research and development.
The acquisition is expected to close during the third quarter of 2021.
Sirion, a privately held company headquartered in German, has approximately 50 employees based in Germany, the United States, and France. The company has established a strong licensing portfolio leveraged by more than a dozen major pharmaceutical and biotech players researching more than twenty-five diseases and conditions.
The addition of SIRION’s offerings will complement PerkinElmer’s Horizon Discovery portfolio, which includes gene editing and modulation tools for CRISPR, CRISPRi, and RNAi; custom cell lines for bio production; and base editing technologies. The deal will also broaden PerkinElmer’s existing cell and gene research solutions featuring high content, in vivo, and cell painting screening technologies; immunoassays; cell plate readers; and advanced automation, microfluidics and informatics and analytical platforms.
“Seventy percent of gene therapy trials today leverage viral vector approaches, and we expect this to remain strong going forward given the demand for targeted, high-payload delivery in treating diseases like cancer,” said Prahlad Singh, president and CEO of PerkinElmer. “By combining Sirion’s innovative “payload” transport technology with our existing Horizon genetic material editing tools and phenotypic research solutions, we will be able to support organizations’ cell and gene therapy workflows as they look to streamline and accelerate their efforts.”
Photo: Prahlad Singh, president and CEO of PerkinElmer